Adial Pharmaceuticals (ADIL) Q2 2025 earnings summary

Executive summary

• Focused on developing AD04 for alcohol use disorder (AUD), with recent positive FDA feedback on clinical endpoints and agreement on key Phase 3 trial design elements.

• Collaboration with Cytel enabled identification of genetically defined subgroups for a precision-driven Phase 3 program.

• Secured U.S.-based manufacturing agreements with Thermo Fisher Scientific and Cambrex to ensure robust supply and reduce risk.

• No products approved or significant revenue generated; operations funded by equity, warrant exercises, and offerings.

• Regained compliance with Nasdaq listing requirements for stockholders' equity.

Financial highlights

• Cash and cash equivalents were $5.9 million as of June 30, 2025, up from $2.4 million as of March 31, 2025.

• Net loss for the six months ended June 30, 2025, was $4.2 million, a significant improvement from $8.9 million in the prior year period.

• Research and development expenses were $1.5 million for the six months ended June 30, 2025, nearly flat year-over-year, with a 28% decrease for Q2.

• General and administrative expenses were $2.7 million for the six months, nearly flat year-over-year, with a 10% decrease for Q2.

• Net cash used in operating activities was $3.3 million for the six months, down from $3.8 million in the prior year.

Outlook and guidance

• Cash on hand is expected to fund operations into Q2 2026, but additional financing is required for ongoing development and planned Phase 3 trials.

• Two additional Phase 3 trials for AD04 are expected to require $8–12 million each, plus up to $5 million in other development expenses.

• Strategic partnership discussions are expected to accelerate following FDA milestone.